



Volume  
71

ADVANCES  
*in* MEDICINE *and*  
BIOLOGY

Leon V. Berhardt  
Editor

NOVA

Complimentary Contributor Copy

**ADVANCES IN MEDICINE AND BIOLOGY**

# **ADVANCES IN MEDICINE AND BIOLOGY**

## **VOLUME 71**

No part of this digital document may be reproduced, stored in a retrieval system or transmitted in any form or by any means. The publisher has taken reasonable care in the preparation of this digital document, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained herein. This digital document is sold with the clear understanding that the publisher is not engaged in rendering legal, medical or any other professional services.

**Complimentary Contributor Copy**

# **ADVANCES IN MEDICINE AND BIOLOGY**

Additional books in this series can be found on Nova's website  
under the Series tab.

Additional e-books in this series can be found on Nova's website  
under the e-book tab.

ADVANCES IN MEDICINE AND BIOLOGY

# ADVANCES IN MEDICINE AND BIOLOGY

## VOLUME 71

**LEON V. BERHARDT**  
**EDITOR**



*New York*

Complimentary Contributor Copy

Copyright © 2013 by Nova Science Publishers, Inc.

**All rights reserved.** No part of this book may be reproduced, stored in a retrieval system or transmitted in any form or by any means: electronic, electrostatic, magnetic, tape, mechanical photocopying, recording or otherwise without the written permission of the Publisher.

For permission to use material from this book please contact us:

Telephone 631-231-7269; Fax 631-231-8175

Web Site: <http://www.novapublishers.com>

### **NOTICE TO THE READER**

The Publisher has taken reasonable care in the preparation of this book, but makes no expressed or implied warranty of any kind and assumes no responsibility for any errors or omissions. No liability is assumed for incidental or consequential damages in connection with or arising out of information contained in this book. The Publisher shall not be liable for any special, consequential, or exemplary damages resulting, in whole or in part, from the readers' use of, or reliance upon, this material. Any parts of this book based on government reports are so indicated and copyright is claimed for those parts to the extent applicable to compilations of such works.

Independent verification should be sought for any data, advice or recommendations contained in this book. In addition, no responsibility is assumed by the publisher for any injury and/or damage to persons or property arising from any methods, products, instructions, ideas or otherwise contained in this publication.

This publication is designed to provide accurate and authoritative information with regard to the subject matter covered herein. It is sold with the clear understanding that the Publisher is not engaged in rendering legal or any other professional services. If legal or any other expert assistance is required, the services of a competent person should be sought. FROM A DECLARATION OF PARTICIPANTS JOINTLY ADOPTED BY A COMMITTEE OF THE AMERICAN BAR ASSOCIATION AND A COMMITTEE OF PUBLISHERS.

Additional color graphics may be available in the e-book version of this book.

### **Library of Congress Cataloging-in-Publication Data**

ISBN: 978-1-61489-489-9 (eBook)

ISSN 2157-5398

*Published by Nova Science Publishers, Inc. † New York*

**Complimentary Contributor Copy**

# CONTENTS

<b>Preface</b>		<b>vii</b>
<b>Chapter 1</b>	Review on Optimization of the Formulations of Metronidazole through Different Administration Routes <i>Nan Li, Fengping Tan and Jerry Zhang</i>	<b>1</b>
<b>Chapter 2</b>	The Use of Metronidazole in Cancer Gene Therapy and Targeted Cell Ablation <i>Claire Horvat, David Ackerley and Gabi Dachs</i>	<b>21</b>
<b>Chapter 3</b>	Protective Roles of Glutathione Peroxidases in Diabetes <i>Ruchi Singh, Sudha Chennasamudram and Tetyana L. Vasylyeva</i>	<b>35</b>
<b>Chapter 4</b>	Stem Cell Disorders and Bone Marrow Transplantation <i>Ming Li and Susumu Ikehara</i>	<b>47</b>
<b>Chapter 5</b>	Catalase Gene Mutant Mice: Acatalasemic and Hypocatalasemic Mice <i>Da-Hong Wang, Keiki Ogino, Ken Tsutsui, Kuniaki Sano, Noriyoshi Masuoka, Hitoshi Sugiyama, Masahiro Miyazaki, Hirofumi Fujita, Kazuhisa Taketa and Masana Ogata</i>	<b>57</b>
<b>Chapter 6</b>	What Do Animal Models of Inflammatory Arthritis Teach Us about Bone Damage? <i>Lukasz Kolodziej</i>	<b>69</b>
<b>Chapter 7</b>	Methylprednisolone Use in Autoimmune Diseases <i>Maria Esther Sanchez-Garcia, Federico Urbano Ramirez, Angela Gomez-Garduño, Gema Pulido Cortijo and Angeles Blanco-Molina</i>	<b>77</b>
<b>Chapter 8</b>	Clinical Use of Methylprednisolone in Oncology <i>Gema Pulido-Cortijo, María Esther Sánchez-García, Ignacio Pérez-Valero, M. Teresa Cano-Osuna and M. Auxiliadora Gómez-España</i>	<b>85</b>

<b>Chapter 9</b>	Pretreatment with Methylprednisolone Reduces Adverse Clinical Effects of Inflammatory Response Induced by Heart Surgery and Cardiopulmonary Bypass	<b>93</b>
	<i>Petar M. Vukovic, Miodrag S. Peric and Predrag S. Milojevic</i>	
<b>Chapter 10</b>	Potential Side Effects of Methylprednisolone	<b>101</b>
	<i>Fatih Büyükcım</i>	
<b>Index</b>		<b>107</b>

*Chapter 10*

## POTENTIAL SIDE EFFECTS OF METHYLPREDNISOLONE

*Fatih Büyükcamlar\**

Department of Emergency Medicine, Dışkapı Yıldırım Beyazıt Education & Research  
Hospital, İrfan Baştuğ Street, Ankara, Turkey

### ABSTRACT

Methylprednisolone is a synthetic glucocorticoid used mainly as an anti-inflammatory and immunosuppressant agent for hematologic, allergic, inflammatory, neoplastic, and autoimmune diseases [1]. It is generally used via intramuscular, intravenous and oral route; but also it could be applied locally to synovial spaces, the conjunctival sac, skin, and respiratory tract [1]. At the site of inflammation glucocorticoids can inhibit leukocyte infiltration so it interferes with inflammatory response mediators and suppress immune responses [2, 3]. Glucocorticoids like methylprednisolone are used for various conditions such as replacement therapy in acute and chronic adrenal insufficiency, congenital adrenal hyperplasia; also non-endocrine diseases such as rheumatic disorders, renal diseases (nephritic syndrome, glomerulonephritis etc.), allergic diseases, bronchial asthma and other pulmonary conditions; additionally infectious, ocular, gastrointestinal, hepatic diseases, malignancies and cerebral edema [1]. Furthermore it is used for its neuroprotection effects in case of acute traumatic spinal cord injury and graft-versus-host disease [4]. Besides its useful effects on numerous conditions, it has many side effects. Its side effects include hyperglycemia, increased skin fragility, osteoporosis, weight gain, adrenal insufficiency, muscle weakness, menstrual period irregularity, growth failure, delayed puberty [4-6]. Methylprednisolone has somewhat greater glucocorticoid activity and somewhat less mineralocorticoid activity than prednisolone [1]. Its mineralocorticoid effects can cause salt and water retention, hypertension, potassium depletion and metabolic alkalosis [1]. Additionally use of high-dose steroids for more than a week cause in depletion of adrenal glands because of the suppression of hypothalamic corticotrophin releasing hormone and pituitary adrenocorticotropic hormone [1, 6]. Abrupt cessation of glucocorticoids after prolonged therapy can cause adrenal insufficiency due to suppression of the

---

\* Corresponding author: Tel: +903125962000, Fax: +903123186690, E-mail: fatihbuyukcam@gmail.com.



hypothalamic-pituitary-adrenal axis, which may be fatal [1]. To prevent this effect treatment should be stopped step by step [6].

## INTRODUCTION

Glucocorticoids are one of the most potent and effective anti-inflammatory medication available and widely used in clinical practice [7]. Methylprednisolone is a synthetic glucocorticoid used mainly as an anti-inflammatory and immunosuppressant agent for hematologic, allergic, inflammatory, neoplastic, and autoimmune diseases [1]. Glucocorticoids have numerous effects in carbohydrate, protein and lipid metabolism, effects of glucocorticoids have mainly glucocorticoid effects but also have less mineralocorticoid effects [1].

Glucocorticoids generally used via intramuscular, intravenous and oral route; but also it could be applied locally to synovial spaces, the conjunctival sac, skin, and respiratory tract [1]. At the site of inflammation glucocorticoids can inhibit leukocyte infiltration so it interferes with inflammatory response mediators and suppress immune responses [2, 3].

Glucocorticoids like methylprednisolone are used for various conditions such as replacement therapy in acute and chronic adrenal insufficiency, congenital adrenal hyperplasia; also non-endocrine diseases such as rheumatic disorders, renal diseases (nephritic syndrome, glomerulonephritis etc.), allergic diseases, bronchial asthma and other pulmonary conditions; additionally infectious, ocular, gastrointestinal, hepatic diseases, malignancies and cerebral edema [1]. Furthermore it is used for its neuroprotection effects in case of acute traumatic spinal cord injury and graft-versus-host disease [4].

Besides its useful effects on numerous conditions, it has many side effects. Its side effects include hyperglycemia, increased skin fragility, osteoporosis, weight gain, adrenal insufficiency, muscle weakness, menstrual period irregularity, growth failure, delayed puberty [4-6]. Methylprednisolone has somewhat greater glucocorticoid activity and somewhat less mineralocorticoid activity than prednisolone [1]. Its mineralocorticoid effects can cause salt and water retention, hypertension, potassium depletion and metabolic alkalosis [1]. Additionally use of high-dose steroids for more than a week cause in depletion of adrenal glands because of the suppression of hypothalamic corticotrophin releasing hormone and pituitary adrenocorticotrophic hormone [1, 6]. Abrupt cessation of glucocorticoids after prolonged therapy can cause adrenal insufficiency due to suppression of the hypothalamic-pituitary-adrenal axis, which may be fatal [1]. To prevent this effect treatment should be stopped step by step [6].

## ENDOCRINOLOGIC SIDE EFFECTS

Glucocorticoids regulate the production of gluconeogenic substrates and activity, also they reduce the glucose utilization by peripheral tissues and increase the oxidation of fats for energy production [8, 9]. Glucocorticoids stimulate hepatic gluconeogenesis from amino acids and glycerol; inhibit glucose uptake in adipose tissue; in peripheral tissues they reduce

glucose usage and increase gluconeogenesis [1, 6, 9]. So glucocorticoids cause increased carbohydrate intolerance and hyperglycemia [4].

Glucocorticoids also cause adrenal suppression, amenorrhea, Cushing's syndrome, diabetes mellitus, hypokalemia, hypokalemic alkalosis, growth suppression in children, hyperlipidemia, irregular menstrual cycle, pituitary-adrenal axis suppression, protein catabolism, sodium and water retention [1, 4, 6].

## **CARDIOVASCULAR SIDE EFFECTS**

Cardiovascular side effects of methylprednisolone mainly result from mineralocorticoid effects of corticosteroids [1, 10]. They may also induce hypokalemia by transcellular potassium shift caused by several mechanisms such as increased  $\text{Na}^+/\text{K}^+$ -ATPase pool in skeletal muscle, steroid induced hyperinsulinemia and hyperglycemia [11-13]. As a result corticosteroids can cause arrhythmias, bradycardia, cardiac arrest, cardiomegaly, circulatory collapse, congestive heart failure, edema, hypertension, hypertrophic cardiomyopathy in premature infants, myocardial rupture (post MI), syncope, tachycardia, thromboembolism, vasculitis [1, 6].

## **CENTRAL NERVOUS SYSTEM SIDE EFFECTS**

Effects of methylprednisolone on central nervous system (CNS) could be divided as direct effects like effects on mood, behavior and brain excitability and indirect effects on CNS by effecting blood pressure, plasma concentrations and electrolyte concentrations [1]. Side effects depends on the dose and the duration of the treatment [14]. The effects could be as follows; delirium, depression, emotional instability, headache, hallucinations, insomnia, increased in intracranial pressure, malaise, nervousness, personality changes, psychotic disorders, seizure and vertigo [15, 16]. In a prospective study; 50 patients received 75-100 mg of prednisone or equivalent for longer than a week for ophthalmologic treatments, 30% of the patients suffered from hypomanic symptoms and 10% from depressive symptoms, but psychosis, dementia and delirium didn't observed [17].

## **IMMUNE SYSTEM SIDE EFFECTS**

Glucocorticoids have immunosuppression potential resulting with increased risk of infections. They inhibit both acquired and innate immunologic functions [18]. Immunologic effects of glucocorticoids are sometimes dose-dependent but also the underlying diseases, comorbid illnesses and other immunosuppressive therapies give additional risks for immunosuppression [19].

Systemic glucocorticoids causes a dose-dependent increase risk of infection especially with bacterial, viral and fungal pathogens [20]. Older patients have higher risk for infection [21]. Additionally patients receiving glucocorticoids may not show symptoms and signs of infection clearly because of the inhibition of cytokine release and associated reduction of

inflammatory and febrile responses [19]. Chronic steroid use can cause increased infection risk in rheumatologic and autoimmune disorders [20, 22].

Live virus vaccines may be applied to patients using prednisone or its equivalent in doses of less than 20 mg/day for 14 days or less; in long term physiologic replacement therapy of glucocorticoids; also in topical (aerosol, intraarticular, bursal or tendon injection) use of them [6]. MMR, Zoster and other live virus vaccines shouldn't be used for one month after cessation of higher doses of glucocorticoids [6].

**Table 1. Major side effects associated with glucocorticoid therapy**

<b>Dermatologic and soft tissue</b>	<b>Renal</b>
Skin thinning and purpura	Hypokalemia
Cushingoid appearance	Fluid volume shifts
Alopecia	<b>Genitourinary and reproductive</b>
Acne	Amenorrhea / infertility
Hirsutism	Intrauterine growth retardation
Striae	<b>Bone</b>
Hypertrichosis	Osteoporosis
<b>Eye</b>	Avascular necrosis
Posterior subcapsular cataract	<b>Muscle</b>
Elevated intraocular pressure/glaucoma	Myopathy
Exophthalmos	<b>Neuropsychiatric</b>
<b>Cardiovascular</b>	Euphoria
Arrhythmias (with intravenous pulse therapy)	Dysphoria / depression
Hypertension	Insomnia / akathisia
Perturbations of serum lipoproteins	Mania / psychosis
Premature atherosclerotic disease	Pseudomotor cerebri
<b>Gastrointestinal</b>	<b>Endocrine</b>
Gastritis	Diabetes mellitus
Peptic ulcer disease	Hypothalamic-pituitary-adrenal insufficiency
Pancreatitis	<b>Infectious disease</b>
Steatohepatitis	Heightened risk of typical infections
Visceral perforation	Opportunistic infections
	Herpes Zoster

\* Saag KG, Furst DE. Major side effects of systemic glucocorticoids. Wolters Kluwer; 2012 [cited 2013 February 20]; Available from: UpToDate.

## DERMATOLOGIC SIDE EFFECTS

Dermatologic side effects of glucocorticoids include acne, allergic dermatitis, alopecia, dry scaly skin, skin atrophy, erythema, sterile abscess, urticaria, edema, hirsutism, hyperpigmentation, hypopigmentation, hypertrichosis, impaired wound healing, petechiae, ecchymoses, rash, skin test reaction impaired, striae [1, 23].

Other major side effects of glucocorticoids also have major side effects on other systems are given in Table 1.

## CONCLUSION

Methylprednisolone is used mainly as an anti-inflammatory and immunosuppressant agent but also it has many side effects. We have to know its potential side effects and inform patients about them.

## REFERENCES

- [1] Schimmer, BP; Parker, KL. Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Brunton LL, editor. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th ed: McGraw-Hill; 2006.
- [2] Schleimer, RP. An overview of glucocorticoid anti-inflammatory actions. *European journal of clinical pharmacology*. 1993, 45 Suppl 1:S3-7; discussion S43-4. Epub 1993/01/01.
- [3] Pitzalis, C; Pipitone, N; Perretti, M. *Regulation of leukocyte-endothelial interactions by glucocorticoids*. Annals of the New York Academy of Sciences. 2002, 966, 108-18. Epub 2002/07/13.
- [4] Methylprednisolone: Drug information. UpToDate: Wolters Kluwer, 2013 (cited 2013 February 12).
- [5] Quinkler, M; Stewart, PM. Hypertension and the cortisol-cortisone shuttle. *The Journal of clinical endocrinology and metabolism*. 2003, 88(6), 2384-92. Epub 2003/06/06.
- [6] Saag, KG; Furst, DE. *Major side effects of systemic glucocorticoids*. Wolters Kluwer; 2012 (cited 2013 February 20), Available from: UpToDate.
- [7] Tsai, WS; Wu, CP; Hsu, YJ; Lin, SH. Life-threatening hypokalemia in an asthmatic patient treated with high-dose hydrocortisone. *The American journal of the medical sciences*. 2004, 327(3), 152-5. Epub 2004/04/20.
- [8] Almon, RR; DuBois, DC; Brandenburg, EH; Shi, W; Zhang, S; Straubinger, RM, et al. Pharmacodynamics and pharmacogenomics of diverse receptor-mediated effects of methylprednisolone in rats using microarray analysis. *Journal of pharmacokinetics and pharmacodynamics*. 2002, 29(2), 103-29. Epub 2002/10/04.
- [9] McMahon, M; Gerich, J; Rizza, R. Effects of glucocorticoids on carbohydrate metabolism. *Diabetes/metabolism reviews*. 1988, 4(1), 17-30. Epub 1988/02/01.
- [10] Fan, JS; Coghlan, JP; Denton, DA; Oddie, CJ; Scoggins, BA; Shulkes, AA. Effect of intravenous infusion of corticosteroids on blood pressure, electrolytes, and water metabolism in sheep. *The American journal of physiology*. 1975, 228(6), 1695-701. Epub 1975/06/01.
- [11] Celsi, G; Nishi, A; Akusjarvi, G; Aperia, A. Abundance of Na(+)-K(+)-ATPase mRNA is regulated by glucocorticoid hormones in infant rat kidneys. *The American journal of physiology*. 1991, 260(2 Pt 2), F192-7. Epub 1991/02/01.
- [12] Ludvik, B; Clodi, M; Kautzky-Willer, A; Capek, M; Hartter, E; Pacini, G, et al. Effect of dexamethasone on insulin sensitivity, islet amyloid polypeptide and insulin secretion in humans. *Diabetologia*. 1993, 36(1), 84-7. Epub 1993/01/01.

- [13] Arzel-Hezode, M; McGoe, S; Sternberg, D; Vicart, S; Eymard, B; Fontaine, B. Glucocorticoids may trigger attacks in several types of periodic paralysis. *Neuromuscular disorders: NMD*. 2009, 19(3), 217-9. Epub 2009/02/10.
- [14] Wolkowitz, OM; Burke, H; Epel, ES; Reus, VI. *Glucocorticoids. Mood, memory, and mechanisms*. Annals of the New York Academy of Sciences. 2009, 1179, 19-40. Epub 2009/11/13.
- [15] Brown, ES; Chandler, PA. Mood and Cognitive Changes During Systemic Corticosteroid Therapy. *Primary care companion to the Journal of clinical psychiatry*. 2001, 3(1), 17-21. Epub 2004/03/12.
- [16] Fardet, L; Petersen, I; Nazareth, I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. *The American journal of psychiatry*. 2012, 169(5), 491-7. Epub 2012/07/06.
- [17] Naber, D; Sand, P; Heigl, B. Psychopathological and neuropsychological effects of 8-days' corticosteroid treatment. *A prospective study. Psychoneuroendocrinology*. 1996, 21(1), 25-31. Epub 1996/01/01.
- [18] Chatham, WW; Kimberly, RP. Treatment of lupus with corticosteroids. *Lupus*. 2001, 10(3), 140-7. Epub 2001/04/24.
- [19] Chatham, WW. *Glucocorticoid effects on the immune system*. Wolters Kluwer, 2013 (cited 2013 May 04), Available from: UpToDate.
- [20] Stuck, AE; Minder, CE; Frey, FJ. Risk of infectious complications in patients taking glucocorticosteroids. *Reviews of infectious diseases*. 1989, 11(6), 954-63. Epub 1989/11/01.
- [21] Sakuma, Y; Katoh, T; Owada, K; Suzuki, H; Sakurai, K; Eiro, M, et al. Initial functional status predicts infections during steroid therapy for renal diseases. *Clinical nephrology*. 2005, 63(2), 68-73. Epub 2005/ 02/26.
- [22] Wolfe, F; Caplan, L; Michaud, K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. *Arthritis and rheumatism*. 2006, 54(2), 628-34. Epub 2006/ 02/01.
- [23] Fardet, L; Flahault, A; Kettaneh, A; Tiev, KP; Genereau, T; Toledano, C; et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion. *The British journal of dermatology*. 2007, 157(1), 142-8. Epub 2007/05/16.